Antibodies to β2-glycoprotein I—a specific marker for the antiphospholipid syndrome

Open Access
Publisher Website
Google Scholar
Abstract
The antiphospholipid syndrome is a disorder characterized by recurrent thrombosis and the presence of antibodies specific to phospholipids. However, the diagnosis of this syndrome is hampered by the lack of a specific laboratory test. In this study an ELISA for the measurement of antibodies to solid‐phase β2‐glycoprotein I (β2‐GPI) was established and compared with anticardiolipin antibodies for diagnosis of antiphospholipid syndrome. Significantly elevated levels of antibodies to β2‐GPI were found in all patients with definite antiphospholipid syndrome (median = 91 AU). Marginally elevated levels of antibodies to β2‐GPI were observed in 5% of patients with systemic lupus erythematosus (SLE; median = 4 AU), 1% with stroke (median = 3 AU), 13% with infectious mononucleosis (median = 3 AU), 10% with HIV infection (median = 3 AU) and 8% with VDRL false‐positive serology for syphilis (median = 4 AU), but not in patients with rheumatoid factor, syphilis or carotid artery stenosis. In contrast, significantly raised levels of anticardiolipin antibodies were observed in 100% of patients with definite antiphospholipid syndrome, 30% with SLE, 88% with HIV infection, 94% with syphilis, 62% with infectious mononucleosis, 9% with rheumatoid factor‐positive sera, 74% VDRL false‐positive serology for syphilis, 47% with stroke and 0% with carotid artery stenosis. This solid‐phase assay for antibodies to β2‐GPI is highly specific for the antiphospholipid syndrome and represents an advance in the laboratory diagnosis of this disorder.

This publication has 0 references indexed in Scilit: